Causes, consequences and clinical significance of aneuploidy across melanoma subtypes

Eva R. Shteinman; Eva R. Shteinman; Eva R. Shteinman; James S. Wilmott; James S. Wilmott; James S. Wilmott; Ines Pires da Silva; Ines Pires da Silva; Ines Pires da Silva; Ines Pires da Silva; Georgina V. Long; Georgina V. Long; Georgina V. Long; Georgina V. Long; Richard A. Scolyer; Richard A. Scolyer; Richard A. Scolyer; Richard A. Scolyer; Ismael A. Vergara; Ismael A. Vergara; Ismael A. Vergara

doi:10.3389/fonc.2022.988691

Frontiers in Oncology (Oct 2022)

Causes, consequences and clinical significance of aneuploidy across melanoma subtypes

Eva R. Shteinman,
Eva R. Shteinman,
Eva R. Shteinman,
James S. Wilmott,
James S. Wilmott,
James S. Wilmott,
Ines Pires da Silva,
Ines Pires da Silva,
Ines Pires da Silva,
Ines Pires da Silva,
Georgina V. Long,
Georgina V. Long,
Georgina V. Long,
Georgina V. Long,
Richard A. Scolyer,
Richard A. Scolyer,
Richard A. Scolyer,
Richard A. Scolyer,
Ismael A. Vergara,
Ismael A. Vergara,
Ismael A. Vergara

Affiliations

Eva R. Shteinman: Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Eva R. Shteinman: Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
Eva R. Shteinman: Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia
James S. Wilmott: Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
James S. Wilmott: Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
James S. Wilmott: Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia
Ines Pires da Silva: Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Ines Pires da Silva: Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
Ines Pires da Silva: Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia
Ines Pires da Silva: Cancer & Hematology Centre, Blacktown Hospital, Blacktown, NSW, Australia
Georgina V. Long: Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Georgina V. Long: Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
Georgina V. Long: Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia
Georgina V. Long: Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia
Richard A. Scolyer: Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Richard A. Scolyer: Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
Richard A. Scolyer: Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia
Richard A. Scolyer: Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and New South Wales (NSW) Health Pathology, Sydney, NSW, Australia
Ismael A. Vergara: Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Ismael A. Vergara: Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
Ismael A. Vergara: Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia

DOI: https://doi.org/10.3389/fonc.2022.988691
Journal volume & issue: Vol. 12

Abstract

Read online

Aneuploidy, the state of the cell in which the number of whole chromosomes or chromosome arms becomes imbalanced, has been recognized as playing a pivotal role in tumor evolution for over 100 years. In melanoma, the extent of aneuploidy, as well as the chromosomal regions that are affected differ across subtypes, indicative of distinct drivers of disease. Multiple studies have suggested a role for aneuploidy in diagnosis and prognosis of melanomas, as well as in the context of immunotherapy response. A number of key constituents of the cell cycle have been implicated in aneuploidy acquisition in melanoma, including several driver mutations. Here, we review the state of the art on aneuploidy in different melanoma subtypes, discuss the potential drivers, mechanisms underlying aneuploidy acquisition as well as its value in patient diagnosis, prognosis and response to immunotherapy treatment.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords